Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor

BJU International

Volumn 91, Issue 3, 2003, Pages 271-277

  Hellawell, G O ^a,c   Ferguson, D J P ^b   Brewster, S F ^c   Macaulay, V M ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Chemosensitivity; Insulin like growth factors type 1 IGF receptor; Prostate cancer

Indexed keywords

ANDROGEN; ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; COMPLEMENTARY RNA; MITOXANTRONE; PACLITAXEL; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL DEATH; CELL SURVIVAL; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; METASTASIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; DOWN-REGULATION; HUMANS; MALE; MITOXANTRONE; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0037326983     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04061.x     Document Type: Article

References (21)

1. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nature Rev Cancer 2001; 1: 34-45
2. Kish JA, Bukkapatnam R, Palazzo F. The treatment challenge of hormone-refractory prostate cancer. Cancer Control 2001; 8: 487-95
3. Hellawell GO, Brewster SF. Growth factors and their receptors in prostate cancer. BJU Int 2002; 89: 230-40
4. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-I receptor in cell-growth, transformation and apoptosis. Biochim Biophys Acta 1997; 1332: F105-26
5. Chan JM, Stampfer MJ, Giovannucci E et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-6
6. Hellawell GO, Turner GDH, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62: 2942-50
7. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001; 61: 6276-80
8. Macaulay VM, Salisbury AJ, Bohula EA, Playford MP, Smorodinsky NI, Shiloh Y. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene 2001; 20: 4029-40
9. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R. Growth-inhibition of human-melanoma cells in nude-mice by antisense strategies to the type-1 insulin-like growth-factor receptor. Cancer Res 1994; 54: 4848-50
10. Werner H, Shalita-Chesner M, Abramovitch S, Idelman G, Shaharabani-Gargir L, Glaser T. Regulation of the insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: implications in human cancer. Mol Genet Metab 2000; 71: 315-20
11. Burfeind P, Chernicky CL, Rininsland F, Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 1996; 93: 7263-8
12. Holding JD, Lindup WE, Bowdler DA, Siodlak MZ, Stell PM. Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck. Br J Clin Pharmacol 1991; 32: 173-9
13. Sun HZ, Wu SF, Tu ZH. Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity. Cell Res 2001; 11: 107-15
14. Scotlandi K, Maini C, Manara MC et al. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther 2002; 9: 296-307
15. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990; 2: 275-80
16. Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000; 92: 34-41
17. Chi KN, Gleave ME, Klasa R et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 3920-7
18. Peruzzi F, Prisco M, Dews M et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999; 19: 7203-15
19. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci USA 2000; 97: 12103-8
20. Resnicoff M, Sell C, Rubini M et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth-factor-i (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994; 54: 2218-22
21. Andrews DW, Resnicoff M, Flanders AE et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001; 19: 2189-200